![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NBPF9 |
Gene summary for NBPF9 |
![]() |
Gene information | Species | Human | Gene symbol | NBPF9 | Gene ID | 400818 |
Gene name | NBPF member 9 | |
Gene Alias | AE01 | |
Cytomap | 1q21.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A087WY26 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
400818 | NBPF9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.65e-02 | 1.27e-01 | 0.0155 |
400818 | NBPF9 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.81e-05 | 4.44e-01 | -0.1088 |
400818 | NBPF9 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.26e-14 | 5.03e-01 | -0.1954 |
400818 | NBPF9 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.48e-02 | 2.06e-01 | 0.096 |
400818 | NBPF9 | HTA11_6818_2000001011 | Human | Colorectum | AD | 3.55e-02 | 3.44e-01 | 0.0112 |
400818 | NBPF9 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.29e-12 | 5.34e-01 | 0.294 |
400818 | NBPF9 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.86e-05 | 1.03e+00 | 0.3487 |
400818 | NBPF9 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.32e-13 | 5.16e-01 | 0.3859 |
400818 | NBPF9 | A015-C-104 | Human | Colorectum | FAP | 7.38e-03 | 1.45e-01 | -0.1899 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NBPF9 | SNV | Missense_Mutation | novel | c.45G>A | p.Met15Ile | p.M15I | protein_coding | tolerated(0.07) | benign(0.042) | TCGA-A2-A0T3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
NBPF9 | SNV | Missense_Mutation | novel | c.1942G>C | p.Glu648Gln | p.E648Q | protein_coding | deleterious(0.01) | probably_damaging(0.955) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
NBPF9 | SNV | Missense_Mutation | novel | c.571G>A | p.Val191Met | p.V191M | protein_coding | tolerated(0.16) | benign(0.05) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
NBPF9 | SNV | Missense_Mutation | novel | c.3124N>G | p.Pro1042Ala | p.P1042A | protein_coding | tolerated(0.19) | possibly_damaging(0.627) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
NBPF9 | SNV | Missense_Mutation | novel | c.1412N>T | p.Pro471Leu | p.P471L | protein_coding | tolerated(0.08) | benign(0.065) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
NBPF9 | SNV | Missense_Mutation | novel | c.1597G>T | p.Asp533Tyr | p.D533Y | protein_coding | deleterious(0.04) | benign(0.043) | TCGA-E2-A14T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
NBPF9 | SNV | Missense_Mutation | novel | c.220N>A | p.Glu74Lys | p.E74K | protein_coding | tolerated(0.18) | probably_damaging(0.955) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
NBPF9 | SNV | Missense_Mutation | novel | c.1044C>G | p.Phe348Leu | p.F348L | protein_coding | tolerated(0.14) | benign(0.108) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
NBPF9 | SNV | Missense_Mutation | novel | c.3127N>A | p.Glu1043Lys | p.E1043K | protein_coding | deleterious(0) | possibly_damaging(0.79) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
NBPF9 | SNV | Missense_Mutation | novel | c.1513G>C | p.Asp505His | p.D505H | protein_coding | tolerated(0.12) | possibly_damaging(0.847) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |